Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (381-390 of 785) with videos related to

Pageof 79
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 7, 2024
How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trialChristoph Wanner, Masaomi Nangaku, Bettina J Kraus, et al.
Ultrasound in Medicine & Biology|December 27, 2008
Heart valve involvement in Fabry cardiomyopathyFrank Weidemann, Joerg M Strotmann, Markus Niemann, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 12, 2015
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 DiabetesMark E Cooper, Vlado Perkovic, Janet B McGill, et al.
Journal of the American College of Cardiology|May 30, 2015
Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patientsGünther Silbernagel, Günter Fauler, Bernd Genser, et al.
Lancet (London, England)|March 19, 2003
Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional studyMarkus Ketteler, Philipp Bongartz, Ralf Westenfeld, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 10, 2025
Predictive Performance of the Cardiovascular Event Risk Test 2 Risk Score in Hemodialysis Patients with ESKDAngelika Witoslawska, Christine Drechsler, Kevin Duarte, et al.
Cardiovascular Diabetology|November 27, 2020
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trialJoão Pedro Ferreira, Subodh Verma, David Fitchett, et al.
Transplantation|February 13, 2015
Homoarginine and Clinical Outcomes in Renal Transplant Recipients: Results From the Assessment of Lescol in Renal Transplantation StudyChristiane Drechsler, Hege Pihlstrøm, Andreas Meinitzer, et al.
Advances in Therapy|December 2, 2024
Addressing the Human Experience of Chronic Kidney Disease: A Call to Transform Kidney CareRicardo Correa-Rotter, Steven J Chadban, Laura Christen, et al.
Journal of the American Society of Nephrology : JASN|May 23, 2003
Oxidized LDL and its compound lysophosphatidylcholine potentiate AngII-induced vasoconstriction by stimulation of RhoAJan Galle, Alexander Mameghani, Steffen-Sebastian Bolz, et al.
Pageof 79

Showing results (381-390 of 785) with videos related to

Sort By:
Pageof 79
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 7, 2024
How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trialChristoph Wanner, Masaomi Nangaku, Bettina J Kraus, et al.
Ultrasound in Medicine & Biology|December 27, 2008
Heart valve involvement in Fabry cardiomyopathyFrank Weidemann, Joerg M Strotmann, Markus Niemann, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 12, 2015
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 DiabetesMark E Cooper, Vlado Perkovic, Janet B McGill, et al.
Journal of the American College of Cardiology|May 30, 2015
Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patientsGünther Silbernagel, Günter Fauler, Bernd Genser, et al.
Lancet (London, England)|March 19, 2003
Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional studyMarkus Ketteler, Philipp Bongartz, Ralf Westenfeld, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 10, 2025
Predictive Performance of the Cardiovascular Event Risk Test 2 Risk Score in Hemodialysis Patients with ESKDAngelika Witoslawska, Christine Drechsler, Kevin Duarte, et al.
Cardiovascular Diabetology|November 27, 2020
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trialJoão Pedro Ferreira, Subodh Verma, David Fitchett, et al.
Transplantation|February 13, 2015
Homoarginine and Clinical Outcomes in Renal Transplant Recipients: Results From the Assessment of Lescol in Renal Transplantation StudyChristiane Drechsler, Hege Pihlstrøm, Andreas Meinitzer, et al.
Advances in Therapy|December 2, 2024
Addressing the Human Experience of Chronic Kidney Disease: A Call to Transform Kidney CareRicardo Correa-Rotter, Steven J Chadban, Laura Christen, et al.
Journal of the American Society of Nephrology : JASN|May 23, 2003
Oxidized LDL and its compound lysophosphatidylcholine potentiate AngII-induced vasoconstriction by stimulation of RhoAJan Galle, Alexander Mameghani, Steffen-Sebastian Bolz, et al.
Pageof 79